PRT2527 Trials

Proven success in rapidly advancing novel therapeutics to clinical trials for cancer patients.

A Phase 1 Study of PRT2527 in Patients with Advanced Solid Tumors (NCT05159518)


Intravenous PRT2527

Trial Status:

Actively Recruiting

Trial Information:

CDK9 is a cyclin dependent kinase and an essential regulator of cancer-promoting transcriptional programs and an important driver in Myc-driven solid tumors and myeloid malignancies. PRT2527 is a potent and highly selective CDK9 inhibitor currently being evaluated in a Phase 1 dose escalation study in patients whose cancers are likely to be dependent on CDK9, including: Myc-dependent solid tumors, sarcoma, prostate and breast cancers.

For full trial information, please visit or contact us directly at [email protected].